Cipla doubles Remdesivir production to meet 'unprecedented' demand

13 Apr 2021 Evaluate

Cipla has doubled production of COVID-19 medication remdesivir to help meet ‘unprecedented demand’ as the country battles a massive second wave of infections. India has overtaken Brazil as the world’s second-worst coronavirus-hit country after the United States, having administered about 107 million vaccine doses among a population of 1.4 billion.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1383.40 -4.50 (-0.32%)
08-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.00
Dr. Reddys Lab 6050.00
Cipla 1383.40
Zydus Lifesciences 1006.10
Lupin 1616.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.